| Dr Erin Pauline Benjamin, DO | |
|
23 Plantation Park Dr Ste 401, Bluffton, SC 29910-6094 | |
| (845) 815-5454 | |
| (843) 757-9665 |
| Full Name | Dr Erin Pauline Benjamin |
|---|---|
| Gender | Female |
| Speciality | Ophthalmology |
| Experience | 15 Years |
| Location | 23 Plantation Park Dr Ste 401, Bluffton, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790052207 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207WX0110X | Ophthalmology - Pediatric Ophthalmology And Strabismus Specialist | D087854 (South Carolina) | Secondary |
| 207W00000X | Ophthalmology | D087854 (South Carolina) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Goulas Eye | 1052545241 | 3 |
News Archive
Anaphylaxis, known to be a sudden and potentially life-threatening allergic reaction, seems to be increasing among children, according to a new study led by a team at the Research Institute of the McGill University Health Centre.
Exercise training is safe in heart failure patients, does not significantly reduce hospitalization or death, but is associated with several improved clinical outcomes, even in those already receiving optimal medical care, researchers reported at the American Heart Association's Scientific Sessions 2008. The Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) was presented as a late-breaking clinical trial.
SureGene has chosen PGXL as laboratory provider for its proprietary STA2R genetic panel, which promises to revolutionize the treatment of schizophrenia.
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers.
Boehringer Ingelheim Pharmaceuticals, Inc. announced that new data from a subgroup analysis of the phase IIb/III LUX-Lung 1 trial show that afatinib (BIBW 2992) reached a four-fold extension (4.4 months vs. 1.0 month for placebo) in progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) patients most likely to have an epidermal growth factor receptor (EGFR) mutation. The updated LUX-Lung 1 data will be presented at the Chicago Multidisciplinary Symposium in Thoracic Oncology.
› Verified 8 days ago
| Entity Name | Goulas Eye |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629419007 PECOS PAC ID: 1052545241 Enrollment ID: O20131001000136 |
News Archive
Anaphylaxis, known to be a sudden and potentially life-threatening allergic reaction, seems to be increasing among children, according to a new study led by a team at the Research Institute of the McGill University Health Centre.
Exercise training is safe in heart failure patients, does not significantly reduce hospitalization or death, but is associated with several improved clinical outcomes, even in those already receiving optimal medical care, researchers reported at the American Heart Association's Scientific Sessions 2008. The Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) was presented as a late-breaking clinical trial.
SureGene has chosen PGXL as laboratory provider for its proprietary STA2R genetic panel, which promises to revolutionize the treatment of schizophrenia.
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers.
Boehringer Ingelheim Pharmaceuticals, Inc. announced that new data from a subgroup analysis of the phase IIb/III LUX-Lung 1 trial show that afatinib (BIBW 2992) reached a four-fold extension (4.4 months vs. 1.0 month for placebo) in progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) patients most likely to have an epidermal growth factor receptor (EGFR) mutation. The updated LUX-Lung 1 data will be presented at the Chicago Multidisciplinary Symposium in Thoracic Oncology.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Erin Pauline Benjamin, DO 23 Plantation Park Dr Ste 401, Bluffton, SC 29910-6094 Ph: (845) 815-5454 | Dr Erin Pauline Benjamin, DO 23 Plantation Park Dr Ste 401, Bluffton, SC 29910-6094 Ph: (845) 815-5454 |
News Archive
Anaphylaxis, known to be a sudden and potentially life-threatening allergic reaction, seems to be increasing among children, according to a new study led by a team at the Research Institute of the McGill University Health Centre.
Exercise training is safe in heart failure patients, does not significantly reduce hospitalization or death, but is associated with several improved clinical outcomes, even in those already receiving optimal medical care, researchers reported at the American Heart Association's Scientific Sessions 2008. The Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) was presented as a late-breaking clinical trial.
SureGene has chosen PGXL as laboratory provider for its proprietary STA2R genetic panel, which promises to revolutionize the treatment of schizophrenia.
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers.
Boehringer Ingelheim Pharmaceuticals, Inc. announced that new data from a subgroup analysis of the phase IIb/III LUX-Lung 1 trial show that afatinib (BIBW 2992) reached a four-fold extension (4.4 months vs. 1.0 month for placebo) in progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) patients most likely to have an epidermal growth factor receptor (EGFR) mutation. The updated LUX-Lung 1 data will be presented at the Chicago Multidisciplinary Symposium in Thoracic Oncology.
› Verified 8 days ago
Dr. David Andrew Hunter, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 10 William Pope Dr, Bluffton, SC 29909 Phone: 843-842-2020 Fax: 843-705-1512 | |
David J Remigio, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 29 Plantation Park Dr, Bluffton, SC 29910 Phone: 843-757-9661 Fax: 843-757-9665 | |
Dr. Scott Michael Anfinson, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 8 Arley Way, Suite 100, Bluffton, SC 29910 Phone: 843-815-5436 Fax: 843-815-7197 | |
Dr. Mark T Goulas, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 23 Plantation Park Dr Ste 401, Bluffton, SC 29910 Phone: 843-815-5454 Fax: 843-757-9665 |